國家衛生研究院 NHRI:Item 3990099045/4446
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 854020      Online Users : 1413
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4446


    Title: Abrogation of skin disease in lupus-prone MRL/Fas(lpr) mice by means of a novel tylophorine analog
    Authors: Choi, JY;Gao, WL;Odegard, J;Shiah, HS;Kashgarian, M;McNiff, JM;Baker, DC;Cheng, YC;Craft, J
    Contributors: National Institute of Cancer Research
    Abstract: Objective. To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-kappa B, on end-organ disease in the MRL-Fas(lpr) murine model of systemic lupus erythematosus (SLE). Methods. Eight-week-old female MRL/Fas(lpr) mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclophosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, bracbial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. Results. DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas(lpr) mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Fas(lpr) mice responds differentially to NF-kappa B inhibitor. Conclusion. DCB-3503 causes significant abrogation of skin disease in MRL/Fas(lpr) mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.
    Date: 2006-10
    Relation: Arthritis and Rheumatism. 2006 Oct;54(10):3277-3283.
    Link to: http://dx.doi.org/10.1002/art.22119
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000241260800027
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33750345392
    Appears in Collections:[Her-Shyong Shiah(1996-2012)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000241260800027.pdf483KbAdobe PDF945View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback